The Hemolung RAS was designed from the ground up to simplify extracorporeal CO2 removal. Simplicity starts with an integrated design approach: the Hemolung Cartridge, Catheter, and Controller work together seamlessly. The Hemolung Cartridge couples a centrifugal blood pump and gas exchange membrane into one device. The Hemolung Controller provides on-screen priming instructions, a real-time display of Hemolung CO2 removal, smart gas flow controls, and one hour of battery life. The Hemolung Catheter is specifically matched to the Hemolung Cartridge to provide circuit flows of 350–550 ml/min with minimal pressure drop all while maintaining superior kink resistance.
With its patented ActiveMix™ technology, the Hemolung RAS is the only device offering highly efficient extracorporeal CO2 removal (30–50% of production) at dialysis-like blood flow rates (less than 550 mL/min). Efficient CO2 removal at low blood flow rates is the key to making ECCO2R less invasive, permitting its use in a broad range of patients.
The Hemolung RAS provides uniquely effective CO2 removal at blood flow rates of just 350–550 mL/min, allowing the use a single 15.5 Fr dual lumen venous catheter, the smallest of any ECCO2R system. Patient mobilization is made possible, particularly when the jugular catheter is used.
The evidence for ECCO2R continues to grow. Offering efficient CO2 removal at low blood flow rates, the Hemolung RAS has applications through the entire continuum of acute respiratory failure. The Hemolung RAS can be utilized to help patients avoid intubation and mechanical ventilation when non-invasive ventilation is failing, for example in cases of acute exacerbation of COPD, providing time for the underlying cause of the exacerbation to be treated. In ventilated patients, the Hemolung RAS can help facilitate ultra-protective lung ventilation strategies, with the goal of reducing of ventilator induced lung injury and expediting lung recovery.
Manufactured by ALung Technologies Inc., U.S.A.